PRA
IONS icon

Parametric Risk Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Parametric Risk Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,606
Closed -$61K – 122
2016
Q2 		$61K Hold
2,606
– – ﹤0.01% 139
2016
Q1 		$106K Buy
+2,606
New +$106K 0.01% 142

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Parametric Risk Advisors's IONS Position: Q3 2016 in Review

Parametric Risk Advisors sold out of Ionis Pharmaceuticals (IONS) in Q3 2016, closing a stake of 2,606 shares — an estimated $61K sold.

Parametric Risk Advisors first reported a position in IONS in Q1 2016 and held it in 2 quarters. The position peaked at $106K in Q1 2016. 281 funds tracked by Wall St. Rank hold IONS as of Q3 2016.

  • Parametric Risk Advisors reported no remaining Ionis Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Parametric Risk Advisors sold 2,606 Ionis Pharmaceuticals shares in Q3 2016, an estimated $61K.
  • Parametric Risk Advisors first reported a position in Ionis Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Parametric Risk Advisors's Ionis Pharmaceuticals position peaked at $106K in Q1 2016.
  • 281 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2016.

Based on Parametric Risk Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.